(Below is a backup copy of the original article with as much credit to the publisher as well as the author that we can provide. By no means do we mean to violate any copyright laws. This page is appearing because someone indicated that the original story was unavailable.)
Over the last few years, the Alzheimer's Drug Discovery Foundation (ADDF) has made significant strides with regards to advanced screening and prevention of the degenerative disorder.
Thanks to funding from philanthropists with connections to companies like Microsoft (MSFT) - Get Microsoft Corporation Report, Amazon (AMZN) - Get Amazon.com Inc. Report, and Estée Lauder, the organization had funded 25 medical research projects aimed at early detection and proactive treatment methods to fight Alzheimer's. And with new donors doubling the non-profit's funding, there's a better chance the medical community can get out ahead of Alzheimer's.
Bill Gates Lead
Image source: Nicolas Liponne/NurPhoto via Getty
Today, Alzheimer's is estimated to affect about 6 million people across America alone. The disease is detectable before side effects occur, meaning that nearly half of those living with Alzheimer's may not even know they have it. This, according to researchers, makes the work the ADDF is doing in the field even more necessary. The disease's onset can be long and slow, meaning there are opportunities for prevention and defensive measures that can improve the quality of life or patients and caretakers across the globe.
Bill Gates Advocates for ADDF's Success
The ADDF has two major goals: to increase the preventative treatment options for Alzheimer's and to make testing for the disease more affordable and accessible. Current testing methods can be incredibly expensive, and current immunotherapy treatments are aimed at slowing the progression once the disease has already become apparent.
Scroll to Continue
TheStreet Recommends
Las Vegas Strip Lead
INVESTING
Forget Covid, the Las Vegas Strip May Have a New Health Problem
31 MINUTES AGO
Bill Gates Lead
TECHNOLOGY
A Sad Bill Gates Makes a Huge Announcement
JUL 13, 2022 3:18 PM EDT
Ukraine Russia Lead JS
TECHNOLOGY
Elon Musk Sounds the Alarm on Russia-Ukraine War
JUL 30, 2022 2:40 PM EDT
Alzheimer's researchers are aiming to identify biomarkers that make it easier to determine which patients are predisposed to the disease. Since its founding, the ADDF has seen progress in researching qualities that may indicate trouble with Alzheimer's in the future.
SPECIAL REPORT: Download TheStreet's 25 Rules for Investing Whitepaper and become a smarter investor.
Bill Gates has spoken at great length about why the organization's Diagnostic Accelerator is the future of Alzheimer's treatment and prevention. Gates actually lost his own father to the disease in 2020, so he's intimately familiar with the effects it can have on a family. The Microsoft magnate believes that the ADDF is on the cutting-edge when it comes to identifying biomarkers for Alzheimer's.
Researchers, funded by the organization, are pursuing testing in a variety of different formats, like easy and affordable run-of-the-mill blood tests. Meanwhile, researchers in Seattle are using artificial intelligence to perform those eye exams geared toward revealing Alzheimer's predisposition in the brain. Gates says that these medical advancements could even lead to apps designed to screen for abnormalities, making access to Alzheimer's prevention easier and more convenient than ever.